Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Overview
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Companies Involved in Therapeutics Development
ALSP Inc
Phelix Therapeutics LLC
Virobay Inc
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Drug Profiles
ALP-496 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CIBP-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit Cathepsin B for Ebola Viral Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Cathepsin B for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cathepsin B for Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-285 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-825 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Dormant Products
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) - Product Development Milestones
Featured News & Press Releases
Apr 19, 2016: American Life Science Pharmaceuticals Obtains Patent
Jan 25, 2016: ALSP invited to Give Oral Presentation at the Keystone TBI Conference January 25-27 in Santa Fe, New Mexico
Nov 14, 2011: Virobay’s Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by ALSP Inc, H1 2020
Pipeline by Phelix Therapeutics LLC, H1 2020
Pipeline by Virobay Inc, H1 2020
Dormant Projects, H1 2020